Dexlevo key facts
as of Oct 2026- Developer of medical aesthetic products intended to enhance skin health through polymer technology.
- Dexlevo is valued at approximately $233.4M as of Oct 2026 (last reported valuation).
- It has raised $69.3M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Smilegate Investment, Shinhan Capital, Small and Medium Business Corporation, Magna Investment (Seoul), SB Partners (South Korea) — 8 tracked in total.
- Status: Privately Held (backing).
Dexlevo's last reported valuation, Nov 2021. Nothing priced has surfaced since.
- ·Watch Dexlevo: the Monday email on marks, rounds and moves
Dexlevo funding rounds
No funding rounds for Dexlevo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Dexlevo valuation
Dexlevo's last reported valuation was $233 million in Nov 2021. No priced round, secondary trade or fund mark has surfaced since.
Dexlevo investors
8 investors are on record for Dexlevo, including Smilegate Investment, Shinhan Capital, Small and Medium Business Corporation and Magna Investment (Seoul).
About Dexlevo
Developer of medical aesthetic products intended to enhance skin health through polymer technology. The company's platform features biodegradable polymers that promote collagen formation and support skin regeneration, enabling healthcare professionals to provide minimally invasive treatments for patients seeking skin rejuvenation.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2013
- Employees
- 96
- Website
- dexlevo.co.kr/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.